Full Press Release Details
itepekimab met primary endpoint in one of two chronic obstructive pulmonary disease copd phase 3 trials.
REGN
itepekimab met primary endpoint in one of two chronic obstructive pulmonary disease copd phase 3 trials
Key Takeaway: itepekimab met primary endpoint in one of two chronic obstructive pulmonary disease copd phase 3 trials